Modify treatment for atopic dermatitis when patient response to dupilumab is partial or non-durable

AbstractPatients with moderate-to-severe atopic dermatitis may have partial or non-durable responses to subcutaneous dupilumab, the first targeted systemic agent approved for this indication. Subsequent management approaches in such patients include optimising topical therapy, considering alternative diagnoses, adjusting the dosage of dupilumab dosage and/or using dupilumab in combination with traditional systemic immunosuppressive agents.
Source: Drugs and Therapy Perspectives - Category: Drugs & Pharmacology Source Type: research